Quincy Chu

589 total citations
19 papers, 478 citations indexed

About

Quincy Chu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Quincy Chu has authored 19 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Quincy Chu's work include Lung Cancer Treatments and Mutations (9 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Quincy Chu is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Quincy Chu collaborates with scholars based in United States, Spain and Canada. Quincy Chu's co-authors include Eric K. Rowinsky, Daniel J. Renouf, Paul C. McDonald, Zaihui Zhang, Madhu Singh, Stephen Chia, Philippe L. Bédard, Shoukat Dedhar, Michael P. A. Lyle and Claudiu T. Supuran and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Quincy Chu

18 papers receiving 474 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Quincy Chu United States	10	284	187	131	122	96	19	478
David A. Rewolinski United States	6	355 1.3×	209 1.1×	249 1.9×	74 0.6×	136 1.4×	7	638
E. Stanbridge United States	3	424 1.5×	71 0.4×	55 0.4×	103 0.8×	165 1.7×	6	502
Mireille Bayle France	8	210 0.7×	109 0.6×	41 0.3×	119 1.0×	61 0.6×	10	406
Adrian Staab Germany	9	255 0.9×	61 0.3×	51 0.4×	52 0.4×	210 2.2×	10	428
Eri Sugiyama Japan	9	193 0.7×	243 1.3×	155 1.2×	30 0.2×	114 1.2×	21	508
Ji Ma China	16	197 0.7×	166 0.9×	50 0.4×	104 0.9×	39 0.4×	40	620
Todd Miller United States	4	267 0.9×	139 0.7×	107 0.8×	179 1.5×	64 0.7×	6	547
Paul Hartman United States	8	147 0.5×	163 0.9×	36 0.3×	69 0.6×	99 1.0×	9	381
Shannon Awrey Canada	13	430 1.5×	196 1.0×	241 1.8×	54 0.4×	188 2.0×	29	773
Ramil Baiazitov United States	9	385 1.4×	207 1.1×	31 0.2×	192 1.6×	128 1.3×	15	666

Countries citing papers authored by Quincy Chu

Since Specialization

Citations

This map shows the geographic impact of Quincy Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quincy Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quincy Chu more than expected).

Fields of papers citing papers by Quincy Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quincy Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quincy Chu. The network helps show where Quincy Chu may publish in the future.

Co-authorship network of co-authors of Quincy Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Quincy Chu. A scholar is included among the top collaborators of Quincy Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Quincy Chu. Quincy Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Yu, Qingzhao, Edward Peters, Edward Trapido, et al.. (2025). Socioeconomic Disparities in Breast Cancer Survival: Examining Potential Mediator Role of Oncotype DX(ODX) Test and Stage at Diagnosis Among HR+/HER2- Breast Cancer Women. Cancers. 17(11). 1802–1802.

2.

Aggarwal, Charu, Alex Martínez‐Martí, Margarita Majem, et al.. (2025). Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer. JAMA Network Open. 8(7). e2518440–e2518440. 1 indexed citations

3.

Martínez‐Martí, Alex, Margarita Majem, Fabrice Barlési, et al.. (2021). LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Annals of Oncology. 32. S1320–S1320. 19 indexed citations

4.

McDonald, Paul C., Stephen Chia, Philippe L. Bédard, et al.. (2020). A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology. 43(7). 484–490. 185 indexed citations

5.

Chu, Quincy, Torsten O. Nielsen, Thierry Alcindor, et al.. (2015). A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200. Annals of Oncology. 26(5). 973–981. 41 indexed citations

6.

Hao, Desirée, Quincy Chu, Stephen Welch, et al.. (2012). A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.. Journal of Clinical Oncology. 30(15_suppl). 3013–3013. 9 indexed citations

7.

Chu, Quincy, Randeep Sangha, Sébastien J. Hotte, et al.. (2012). Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.. Journal of Clinical Oncology. 30(15_suppl). e13011–e13011. 1 indexed citations

8.

Chu, Quincy, Peter Ellis, Linda Mileshkin, et al.. (2010). 412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors. European Journal of Cancer Supplements. 8(7). 131–131. 2 indexed citations

9.

Chu, Quincy, Alain C. Mita, Bahram Forouzesh, et al.. (2010). Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(9). 2656–2665. 22 indexed citations

10.

Forouzesh, Bahram, Manuel Hidalgo, Quincy Chu, et al.. (2009). Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 15(10). 3591–3599. 23 indexed citations

11.

Chu, Quincy, Bahram Forouzesh, Samira Syed, et al.. (2007). A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Investigational New Drugs. 25(4). 359–367. 46 indexed citations

12.

Papadopoulos, Kyriakos P., Quincy Chu, Akash Patnaik, et al.. (2006). Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 2029–2029. 6 indexed citations

13.

Mita, Akira, Quincy Chu, Anthony W. Tolcher, et al.. (2005). Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: Results of a phase I study. Journal of Clinical Oncology. 23(16_suppl). 3082–3082. 7 indexed citations

14.

Schwartz, Garry, Quincy Chu, L. A. Hammond, et al.. (2004). Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3070–3070. 20 indexed citations

15.

Mita, Monica, Eric K. Rowinsky, Akira Mita, et al.. (2004). Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. Journal of Clinical Oncology. 22(14_suppl). 3076–3076. 34 indexed citations

16.

Rowinsky, Eric K., Alain C. Mita, S. Syed, et al.. (2004). 409 AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies — a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study. European Journal of Cancer Supplements. 2(8). 122–122. 3 indexed citations

17.

Chu, Quincy, Lisa A. Hammond, Garry Schwartz, et al.. (2004). Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies. Clinical Cancer Research. 10(15). 4913–4921. 43 indexed citations

18.

Williams, Daphne, Steven J. Kathman, Quincy Chu, et al.. (2004). 55 A phase I study of SB-715992, a novel kinesin spindle protein (KSP) inhibitor: pharmacokinetic (PK)/pharmacodynamic (PD) modeling of absolute neutrophil counts (ANC). European Journal of Cancer Supplements. 2(8). 20–21. 3 indexed citations

19.

Schwartz, Garry, Quincy Chu, L. A. Hammond, et al.. (2004). Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3070–3070. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact